Technical Analysis for COCP - Cocrystal Pharma, Inc.

Grade Last Price % Change Price Change
F 1.08 -2.70% -0.03
COCP closed down 2.7 percent on Thursday, May 13, 2021, on 56 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down
Historical COCP trend table...

Date Alert Name Type % Chg
1,2,3 Pullback Bullish Bullish Swing Setup 0.00%
Calm After Storm Range Contraction 0.00%
Narrow Range Bar Range Contraction 0.00%
NR7 Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Down 3 Days in a Row Weakness 0.00%
Down 4 Days in a Row Weakness 0.00%
Down 5 Days in a Row Weakness 0.00%
Oversold Stochastic Weakness 0.00%
1,2,3 Pullback Bullish Bullish Swing Setup -2.70%
Older End-of-Day Signals for COCP ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Down 3% about 6 hours ago
Possible NR7 about 6 hours ago
60 Minute Opening Range Breakdown about 6 hours ago
Down 2 % about 9 hours ago
Down 1% about 10 hours ago
View Earlier Intraday Alerts

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Cocrystal Pharma, Inc. Description

Cocrystal Pharma, Inc. is a clinical stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of hepatitis viruses, influenza viruses, and noroviruses. Cocrystal employs unique structure-based technologies and Nobel Prize winning expertise to create first- and best-in-class antiviral drugs. CC-31244 is a Phase 2a ready broad-spectrum novel non-nucleoside replication inhibitor of HCV. Phase 1b studies in HCV infected patients showed the largest reduction in viral load of any non-nucleoside inhibitor tested to date. The next step for CC-31244 is clinical trials as part of a cocktail for ultra-short therapy of 2 to 4 weeks. The lead candidate for influenza has advanced to IND-enabling studies. It is effective in animal models against both the pandemic and seasonal strains of influenza. In addition, the Company has a pipeline of promising early preclinical programs. Two private investors own approximately 60% of the Company, including the Frost Group. OPKO Health, Inc., Brace Pharma Capital, LLC and Teva Pharmaceuticals Industries, Ltd. are corporate investors.


Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Biology Influenza Coronavirus Viruses Microbiology Antiviral Drug Virus Biocides HCV Influenza Viruses Opko Health Pharmaceuticals Industries

Is COCP a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 3.46
52 Week Low 0.76
Average Volume 18,002,268
200-Day Moving Average 1.40
50-Day Moving Average 1.38
20-Day Moving Average 1.27
10-Day Moving Average 1.33
Average True Range 0.23
ADX 34.25
+DI 43.62
-DI 15.45
Chandelier Exit (Long, 3 ATRs ) 2.76
Chandelier Exit (Short, 3 ATRs ) 1.76
Upper Bollinger Band 1.71
Lower Bollinger Band 0.84
Percent B (%b) 0.28
BandWidth 68.46
MACD Line -0.05
MACD Signal Line -0.03
MACD Histogram -0.0217
Fundamentals Value
Market Cap 74.05 Million
Num Shares 68.6 Million
EPS -1.47
Price-to-Earnings (P/E) Ratio -0.74
Price-to-Sales 39.86
Price-to-Book 2.24
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.20
Resistance 3 (R3) 1.21 1.17 1.18
Resistance 2 (R2) 1.17 1.14 1.17 1.17
Resistance 1 (R1) 1.13 1.12 1.11 1.12 1.17
Pivot Point 1.09 1.09 1.09 1.09 1.09
Support 1 (S1) 1.05 1.06 1.03 1.04 0.99
Support 2 (S2) 1.01 1.04 1.01 0.99
Support 3 (S3) 0.97 1.01 0.98
Support 4 (S4) 0.96